Effectiveness of ETI Combination Therapy for N1303K CFTR Variant
发布者：Unknown
·发布于: 2025-12-13
Discussion regarding the effectiveness of Elexacaftor + Tezacaftor + Ivacaftor (ETI) combination therapy in restoring CFTR function specifically for Cystic Fibrosis patients with the N1303K variant.